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Mammalian placentation is a vital facet of the development of a healthy and viable offspring. Throughout gestation the placenta
changes to accommodate, provide for, and meet the demands of a growing fetus. Gestational gene expression is a crucial part of
placenta development. The endocannabinoid pathway is activated in the placenta and decidual tissues throughout pregnancy and
aberrant endocannabinoid signaling during the period of placental development has been associated with pregnancy disorders. In
this study, the gene expression of eight endocannabinoid system enzymes was investigated throughout gestation. Rat placentae were
obtained at E14.25, E15.25, E17.25, and E20, RNA was extracted, and microarray was performed. Gene expression of enzymes Faah,
Mgll, Plcd4, Pld1, Nat1, Dagl𝛼, and Ptgs2 was studied (cohort 1, microarray). Biological replication of the results was performed
by qPCR (cohort 2). Four genes showed differential expression (Mgll, Plcd4, Ptgs2, and Pld1), from mid to late gestation. Genes
positively associated with gestational age were Ptgs2, Mgll, and Pld1, while Plcd4was downregulated.This is the first comprehensive
study that has investigated endocannabinoid pathway gene expression during rat pregnancy.This study provides the framework for
future studies that investigate the role of endocannabinoid system during pregnancy.
1. Introduction
During gestation, products of the endocannabinoid system
in the placenta are crucial for maintenance of pregnancy
and for both the onset and progression of labor [1]. The
endogenous ligands for this system, the endocannabinoids,
are formed from membrane phospholipids. Two well char-
acterised endocannabinoids are 2-acylglycerol (2AG) and
anandamide (AEA). These molecules are not stored within
cells but are synthesised and released in response to increased
substrate availability and synthase activity [2]. 2AG and
AEA bind to the G-coupled protein receptors, cannabinoid
receptors 1 and 2 (CB1 and CB2) [1]. The loss of the
CB receptors has been linked to preterm delivery which
accounts for 5–18% of pregnancies worldwide [3, 4].Thus this
complex endocannabinoid systemmay play a role in preterm
birth [5].
The endocannabinoid synthesis system is complex
(Figure 1). AEA is believed to be formed by a two-step
catalysis in which arachidonic acid is transferred to a phos-
pholipid precursor, phosphatidylethanolamine, by N-acyl-
transferases (NATs) to form N-arachidonoyl phosphati-
dylethanolamine (NAPE). NAPE is cleaved by phospholipase
D (PLD) to form AEA [6]. 2AG is synthesised from diacyl-
glycerol through the action of diacylglycerol lipase (DAGL)
[7]. Diacylglycerol is formed from phosphoinositides by the
action of an important enzyme, phospholipase C (PLC).
The liberation of arachidonic acid occurs via the catalysis
of enzyme phospholipase A2 or indirectly by the catalyses
of PLC and DAGL and monoacyl glycerol lipase enzymes
(MAGL, protein coded byMgll) [8]. FAAH converts AEA to
arachidonic acid and ethanolamine (Figure 1).
Arachidonic acid can be converted to PGH2 by the
enzymes PTGS-2 and PTGS-1. PGH2 is further converted
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Figure 1: Endocannabinoid system giving rise to endocannabinoids (2AG and AEA) and arachidonic acid and subsequently synthesis of
prostaglandin glycerol esters, prostanoids, and prostamides.
to other key downstream molecules/metabolites of the
eicosanoid family (prostaglandin glycerol esters, prostanoids,
and prostamides) that have been studied for their instru-
mental roles in the aetiology of labor, namely, TxA2, PGD2,
PGE2, PGI2 and PGF2a, and so forth (Figure 1). These are
synthesised by the action of other downstream enzymes.
PTGS2 is crucial for its multifactorial role, as it also converts
anandamide to PGH2-E and 2AG to PGH2-G [9]. In rat
placenta, 2AG and AEA play important roles in fetoplacen-
tal development and aberrant cannabinoid signalling can
cause pregnancy complications [10, 11]. PGF2𝛼 is particularly
important for labor since it induces myometrial contractility
[12–14].
This paper focuses on the endocannabinoid system from
mid to late gestation leading up to the period just prior to
labor. Distorted expression of genes and their metabolites
of the endocannabinoid system can result in spontaneous
miscarriage and poor pregnancy outcomes such as preterm
birth. Recently it has been suggested that the endocannabi-
noid profiles can serve as biomarkers in a clinical setting
to identify and/or predict spontaneous preterm labor [15].
To date, limited studies have reported on placental gene
expression of these enzymes from mid pregnancy to labor.
The aim of this study is to compare the expression changes
of eight enzymes involved in the endocannabinoid system
from rat placenta taken at 4 gestational stages E14.25, E15.25,
E17.25, and E20. Placentae from two independent cohorts
were used in this study. The hypothesis of this study was that
endocannabinoid enzyme expression would change (either
increase or decrease) throughout gestation, in support of
a normal gestation. Although placental factors cannot be
used directly as biomarker(s) to predict and/or identify
spontaneous labor onset in a clinical setting, as placental
biopsies will not be available prior to labor, the study may
be able to provide insight into what factors need further
investigation in biological fluids that can be quantified during
pregnancy.
2. Methods and Materials
2.1. StudyDesign. Geneswere selected based on their involve-
ment in the endocannabinoid system (as shown in Figure 1),
specifically genes for enzymes that are involved in the synthe-
sis of the molecules PGH2, AEA, and 2AG and arachidonic
acid, namely,Plc, Dagl𝛼,Mgll, Nat, Faah, Pld, Ptgs1, andPtgs2.
The expression of these genes, except Ptgs1, was analyzed
using microarray on a first cohort of rat placental samples.
A second cohort of independent samples was then used for
biological replication as validation by qPCR as shown in
Figure 2.
2.2. Animals and Diets. All animal experiments were per-
formed with the approval of The School of Biomedical
Sciences’ Animal Ethics Committee of Monash Univer-
sity. Experiments were carried out in accordance with the
National Health and Medical Research Council of Australia
“AustralianCode of Practice for the Care andUse of Animals for
Scientific Purposes” (7th edition, 2004). Sprague Dawley rats
were used throughout this study. Healthy dams were allowed
to adapt to the animal house for one week. They were fed a
standard chow diet (20% protein, 68% carbohydrate, and 12%
fat) and water ad libitum in a light controlled environment
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Table 1: Primer sequences (forward and reverse) and product lengths for all genes used in qPCR experiments.
Gene Product Forward primer Reverse primer
Ptgs2 201 bp TCACCCGAGGACTGGGCCAT CAGCGAACCGCAGGTGCTCA
Mgll 240 bp CGCGCAGTAGTCTGGCTCT AAGATGAGGGCCTTGGGTGTG
Plcd4 182 bp CTTCCAGTCGTCAGACTACCC CCAAGATCTTCCCCCGAAGC
Faah 218 bp CAACCGCCTCAGCAAGAGTG CATAGTACCCCACACGCAGG
Dagla 121 bp CTTGGACTCAGCCCTGGAC GAACTGGGATGAAGGGGGTG
Nat1 240 bp TCACTCGCCATGGCATTCTC AGCCTGGCTTGCTTTTACCT
Pld1 224 bp CCCCCATCTCGACTTTCAACT TCCCGGGTGTCGAGATTTTC
Ptgs1 145 bp TAGGCCATGGGGTAGACCTT TTCACGGACGCCTGTTCTAC
𝛽-actin 119 bp TCCACCCGCGAGTACAACCT TTGCACATGCCGGAGCCGTT
Selected genes of the endocannabinoid pathway
Phospholipase C (Plc), diacylglycerol lipase (Dagl𝛼), monoacyl
glycerol lipase (Mgll), N-acyltransferases (Nat), fatty acid
amide hydrolase (Faah), phospholipase D (Pld), prostaglandin-
endoperoxide synthase (Ptgs2)
qPCRMicroarray
Cohort 2Cohort 1
gestational age group
N = 6 placentae per
gestational age group
N = 4, 6 placentae per
Figure 2: Study design: two independent cohorts of rat placenta
samples used for microarray (cohort 1) and qPCR (cohort 2). In
cohort 2, we used E14.25, 𝑛 = 6, E15.25, 𝑛 = 4, E17.25, 𝑛 = 6, and
E20, 𝑛 = 6. Note: Ptgs1 was only analyzed by qPCR.
(12 h light/dark cycle) throughout the study. Female rats
were time-mated for 3 h with male Sprague Dawley rats,
to reduce variability of gestational age among the offspring
and to maximize the accuracy in staging of gestation. Dams
were individually housed after mating. Both cohort samples
(cohorts 1 and 2) were fed and treated in the same fashion to
maintain consistency.
2.3. Tissue Collection. Pregnant dams were anaesthetized
(Isoflurane Rhodia Australia P/L, VIC, Australia) and
humanely killed at embryonic days (E) 14.25, 15.25, 17.25, and
20 (𝑛 = 6 per gestational age).Whole placentaewere collected
from each of the pregnant dams, weighed, and snap-frozen
in liquid nitrogen. Tissues were stored at −80∘C until being
processed and analyzed.
2.4. RNA Isolation. Using a mortar and pestle, rat placental
tissues were pulverized into a very fine powder using liquid
nitrogen. Total RNA was extracted from 30mg of pulverized
frozen placental tissue using the AllPrep DNA/RNAMini Kit
(Qiagen) as per manufacturers’ instructions. Genomic DNA
removal was ensured by an on-column Dnase1 treatment
step. Total RNAwas quantified via NanoDropND-1000 spec-
trophotometer (Thermo Scientific, DE, USA). RNA integrity
was verified using an Agilent 2100 Bioanalyzer (VIC, Aus-
tralia), by RIN (RNA Integrity Number) score measurements
prior to the analysis. RNA samples that fulfilled the following
criteria were selected for microarray analysis: (i) RIN > 8.5;
(ii) 260/280 ratio > 2; (iii) 260 : 230 > 1. All RIN scores were
greater than 8.7.
2.5. Microarray Analysis on Illumina Rat Ref Arrays. For
the microarray analysis, 500 ng of total RNA was converted
to double stranded cDNA and this was used to generate
biotinylated cRNA probes using the Illumina TotalPrep
RNA Amplification Kit. Biotin-labelled cRNA were then
hybridized to Illumina RatRef-12 Expression BeadChip (San
Diego, CA, USA). Slides were scanned on a BeadStation 500
System using Beadscan software Version 3.5.31. Each of the
placental samples was analysed independently. Array experi-
ment readout was deposited on ArrayExpress (ArrayExpress
accession number E-MTAB-1987). Overallmicroarray results
were previously published by our group [16]. For this study,
expression of the 7 enzymes Faah, Mgll, Plcd4, Pld1, Nat1,
Dagl𝛼, and Ptgs2 in the endocannabinoid system was ana-
lyzed.
2.6. Quantitative Real-Time PCR Validation Experiments.
qPCR was used to confirm and validate the expression of
8 genes, Faah, Mgll, Plcd4, Pld1, Nat1, Dagl𝛼, Ptgs1 (data
not shown, not carried out in microarray), and Ptgs2 in
an independent cohort on an ABI StepOne PCR machine.
All primers were designed specifically for rat sequences
only spanning intron junctions, to eliminate amplification of
genomic DNA. The primer sequences are listed in Table 1.
Supplementary Figure S2 (see Supplementary Material avail-
able online at http://dx.doi.org/10.1155/2015/850471) displays
the amplification products of the various genes using these
primers displayed in Table 1. 𝛽-actin was used as the endoge-
nous control gene and relative expression was calculated
using the ΔΔCT method.
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Figure 3: Continued.
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Figure 3: Differential expression of seven eicosanoid enzyme genes assessed by microarray (cohort 1) and validated by qPCR (cohort 2). The
left panel shows the results of the microarray analyses; the right panel displays the results of the qPCR. (a) Ptgs2 by microarray in cohort 1
has been previously published. The level of statistical significance is shown as asterisk. Gene expression changes were considered significant
when gene expression was changed by >2 (∗𝑃 < 0.05; ∗∗𝑃 < 0.005; ∗∗∗𝑃 < 0.001; ∗∗∗∗𝑃 < 0.0001; and ns𝑃 > 0.05).
3. Results
3.1. Gestational Age-Related Expression Changes of 4 Endo-
cannabinoid System Enzymes. Of the 7 endocannabinoid
enzymes involved in the metabolism of endocannabinoids,
4 (Ptgs2, Mgll, Plcd4, and Pld1) were differentially expressed
in cohort 2 samples by qPCR. Cohort 1 samples showed
differential expression of Ptgs2, Mgll, and Plcd4 but not Pld1
(Figure 3). Ptgs2 showed a marked increase in expression
between E17.25 and E20 of fold change of >2.5 (𝑃 < 0.001),
Mgll showed consistent 3-fold increase from E15.25 to E17.25
(𝑃 < 0.05; qPCR and <0.001; microarray), and Plcd4 showed
a gradual decrease in expression from E14.25 to E15.25 (fold
change approximately 2,𝑃 < 0.05) and E17.25 with expression
remaining relatively low at E20 just prior to labor onset. A
gene expression pattern for these 3 genes (Ptgs2, Mgll, and
Plcd4) is shown in Figure 4.
3.2. Gene Expression That Remained Unchanged from Mid
to Late Gestation. The gene expressions of 8 enzyme genes
were carried out, out of which Nat1, Dagl𝛼, and Faah
expression remained relatively stable throughout gestation
in both cohorts 1 (microarray) and 2 (qPCR) as shown
in Figure 3. Ptgs1 (data not shown) was only studied by
qPCR and showed no differential expression (constitutive
expression), consistent with literature.
3.3. Other Endocannabinoid Genes Whose Expression
Remained Relatively Stable in Microarray. Interestingly the
expression of other genes in the system that were stable over
the course of gestation included the phospholipases Plcb3,
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Figure 4: Proposed relationship of the 3 differentially expressed
genes Ptgs2, Plcd4, and Mgll from mid to late gestation from qPCR
results.
Plcd3, Plcl3, Plcz1, Pld2 and Pld3, and Nat2 and Nat3; the
genes for phospholipase 2 isotypes Pla2g15, Pla2g2d, Pla2g2e,
Pla2g3, and Pla2g5; and genes for cannabinoid receptors CB1
and CB2, that is, Cnr1 and Cnr2 (data not shown).
4. Discussion
This study is the first to highlight differential expression of
4 genes (Plcd4, Ptgs2, Pld1, and Mgll) in rat placenta from
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mid-late gestation to labor onset. Our study expands on
a previous study [11] in rat placenta that has focused on
expression of CB1 and CB2 endocannabinoid receptor, genes
(Cnr1 and Cnr2), and some genes of the endocannabinoid
system. Most other studies of placenta from normal and
pathological pregnancies have focused on the downstream
prostaglandins (particularly PGH2) as an end product, some
with the involvement of Ptgs1 and Ptgs2, during the onset of
labor [17]. Consistent with previous literatureDagl𝛼 and Faah
expression [11] and Ptgs1 and Nat1 expression remained stable
throughout the four gestational ages.
4.1. Ptgs2 and Ptgs1 in This Study and in Pregnancy. Ptgs1
and Ptgs2 have been widely studied in placentae of women
and animals models for decades [18]. Here we observe that
expression of Ptgs2 in whole rat placenta in both cohorts
remained stable throughout E14.25, E15.25, and E17.25 but
was significantly upregulated at E20, just before the onset of
labor, consistent with previous studies [16, 19–21]. Since Ptgs1
and Ptgs2 are directly involved in prostaglandin syntheses,
any differential or aberrant expression of these two enzymes
may have a dramatic effect in prostaglandin levels [19]. We
also know that Ptgs2 is an inducible gene, which may be
triggered to initiate the labor process. However it cannot
be determined conclusively whether the increase of Ptgs2
leads to prostaglandin production, which then triggers the
labor process (which is the ongoing hypothesis in various
animal studies). In fact, some studies have suggested that
PGs originating in the fetal membranes are a trigger for
the onset of normal labor [21]. This sudden observed spike
in Ptgs2 expression is associated with increased production
of prostaglandins. Increased prostaglandins are observed
just prior to and during labor. Further studies on Ptgs2 in
mammalian pregnancy and labor onset are required given
its variable expression and vital role in the biosynthesis of
prostaglandins. Ptgs1 on the other hand is a constitutively
expressed gene and by qPCRdemonstrated that its expression
remained relatively stable throughout mid to late gestation
(data not shown). Ptgs2 is important in the endocannabinoid
system and there is now evidence to show that factors (PGE2,
Ptgs2, etc.) involved in this pathway in placenta may have a
role in ovulation, implantation, and decidualization [22, 23]
and abnormal expression may result in spontaneous miscar-
riage, placental abruptions, and poor pregnancy outcomes
[24, 25]. Prostaglandins increase myometrial sensitivity and
PTGS2 is especially associated with changing myometrial
contractility during pregnancy [26]. In a clinical setting,
selective PTGS2 inhibition is used to delay premature onset
of labor [13]. Although nonsteroidal anti-inflammatory drugs
(NSAIDs), which inhibit PTGS2, are usually successful in
suppressing preterm labor or prolonging pregnancy in animal
and human studies, the NSAIDs have adverse effects on fetal
physiology and development, including renal defects and
cardiomyopathies [5, 26, 27].The need then arises for another
approach to predict and treat preterm labor. Fluctuations in
gene expression and enzyme concentrations and metabolite
production may serve as useful indicators of labor onset.
These factors, their metabolites, and substrates may then
be further investigated in biological fluids to study their
potential as biomarkers for early detection of preterm birth
and hence pregnancies where there is a risk of preterm
delivery to be captured early.
Ptgs2 regulation occurs at many levels [28] and is affected
by transcription factors, activator proteins, and chromatin
remodelling. Moreover, the endocannabinoid system has
come under scrutiny given that several microRNAs such
as miR26, miR146, and miR10 are responsible for its gene
regulation [28, 29]. These have emerged as regulators of
not only physiological processes of pregnancy and labor,
such as uterine contractions [30–32]. A future study to
link gene regulation patterns and labor is necessary. Also,
other prostaglandin and thromboxane molecules should be
investigated further to determine their roles in pregnancy and
the inflammatory process.
4.2. Phospholipase C (PLC). Interestingly, another novel gene
that showed significant differential expression was Plcd4.
Plcd4 expression was relatively high at E14.25 and gradually
decreased at E15.25, E17.25 and further decreased at E20.Plcd4
expression was significantly reduced just prior to labor onset
in both cohorts. Arachidonic acid can be synthesized through
the conversion of phosphoinositides to diacylglycerol by PLC.
The results perhaps indicate that the product of this enzyme,
diacylglycerol, is reduced and that PLCD4 may be necessary
to control levels of diacylglycerol and subsequently 2AG and
PGH2-G. This control mechanism could be an important
player in the process of labor and hence this study should
be further expanded in preterm samples as there is a paucity
of data with regard to the role of Plcd4 in pregnancy. Apart
from identifying the presence of the gene transcripts in
myometrium from pregnant versus nonpregnant rats, Plcd4,
unlike phospholipase A [16, 33], has not been studied for
its role in placenta especially with its link to labor and
parturition. Nevertheless PLCD4 can be further investigated
in human samples as a potential biomarker for preterm
deliveries in perhaps other gestational tissues, including
membranes and/or biological fluids, and a reduced level
of the enzyme could be a useful prognostic for impending
preterm birth.
Another gene to be highlighted in this study for its
marked gene expression change from E15.25 to E17.25 isMgll
where a 2-fold increase was observed in both cohorts (E15.25
to E17.25). This increase likely indicates that downstream
synthesis of arachidonic acid may be present. An increase of
arachidonic acid at E17.25 and then a subsequent increase in
expression of Ptgs2 at E20 are likely to increase arachidonic
acid derived PGH2. Interestingly, when Plcd4 expression is at
its lowest level, then Ptgs2 expression is at its highest level, just
prior to labor. A relationship between the 3 genes Ptgs2, Mgll,
and Plcd4 and time points of gestation is shown in Figure 4.
4.3. Other Endocannabinoid System Genes. From qPCR
results on cohort 2 samples,Pld1 expression increased steadily
from E14.25, E15.25, and E17.25 to E20. Interestingly microar-
ray signals were below the level to detect change as it has a
very low expression level overall. Steady expression of Faah
across gestation observed in the present study is consistent
with the findings of Mijovic et al. in rat placenta [15].
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Figure 5: Proposed model of gestational related changes in gene expression of endocannabinoid system genes, as pregnancy progresses from
mid to late gestation in rat placenta.
In both qPCR and microarray, the expression profile of
Dagl𝛼 is consistent with the literature [15]. Dagl𝛼 and Nat1
expression were both observed to remain stable in mid to
late gestation, indicating their constitutive expression during
this time window likely maintaining the function of their by-
products of metabolism NAPE (precursor for anandamide)
and 2AG, respectively, throughout pregnancy. Interestingly
the expressions of other enzyme genes, in microarray, in the
system that did not change during the gestation window are
Nat3, Plcb3, Plcd3, Plcl3, Plcz1, Pld2, Pld3, Pla2g15, Pla2g2d,
Pla2g2e, Pla2g3, and Pla2g5 (data not shown). Other related
genes from microarray data are shown in Supplementary
Figure S1.
From the results of this study, summarized in Figure 5,
increasing gestational age is associated with increasing syn-
thesis of PGH-2 (and downstream metabolites, prostanoids,
and prostamides) from AA and AEA, respectively (Figure 5).
On the other hand, the formation of prostaglandin glycerol
esters may be downregulated as gestation progresses. Both
AEA andAAaremetabolites of PLD andMAGL, respectively,
and genes for these two enzymes show upregulation from
mid to late gestation. This is complemented by the study
by Fonseca et al., 2012, which shows that AEA levels in the
placenta gradually increased reaching maximum level on day
19 of gestation, while expression remained lower on days
14 and 16 [11]. The downregulation in Plcd4 may indicate a
control mechanism that reduces the synthesis of 2AG and
hence PGH2-G and its derivatives. There is a paucity of
data pertaining to the formation of glycerol esters in late
stage pregnancy and labor. This shift in gene regulation
away from 2AG metabolism may be key in studying and
choosing the metabolites for prediction of preterm birth.
Furthermore, it is predicted that increases in arachidonic acid
concentration would arise by 2AG and AEA metabolism,
prior to PGH2 formation by PTGS2. The data provides an
opportunity to further elucidate functional pathways that
may be of significance in late placental function in both
normal and pathological pregnancies.
5. Conclusion
From the results of this study, late gestation is associated with
the synthesis of PGH-2 (and their downstream metabolites,
prostanoids, and prostamides) from AA and AEA, respec-
tively. The formation of prostaglandin glycerol esters may
be downregulated as gestation progresses. In this study, we
show that the genes for PLD and MAGL, which catalyse the
synthesis of both AEA and AA, are upregulated from mid to
late gestation, while the Plcd4 expression is downregulated.
This may indicate a regulatory mechanism that reduces the
synthesis of 2AG and hence PGH2-G and its derivatives.This
shift in gene regulation away from 2AG metabolism could
be a key pathway for the identification of metabolites for the
prediction of preterm birth.
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